Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 5, 2009, Pages 411-417

  Togami, Kohei ^a   Chono, Sumio ^a   Seki, Toshinobu ^a,b   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^b JOSAI UNIVERSITY   (Japan)

Author keywords

Alveolar macrophages; Calu 3; Ketolide; Lung epithelial lining fluid; MDR1; NR8383; Telithromycin

Indexed keywords

CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; KETOLIDE; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123; ROTENONE; TELITHROMYCIN; VERAPAMIL;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BASOLATERAL MEMBRANE; CELL LEVEL; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; EXTRACELLULAR SPACE; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; MAXIMUM PLASMA CONCENTRATION; MONOLAYER CULTURE; NONHUMAN; RAT; TEMPERATURE DEPENDENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 71449110365     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.411     Document Type: Article

References (45)

1. Ackermann, G. and Rodloff, A. C.: Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J. Antimicrob. Chemother., 51: 497-511 (2003).
2. Wootton, M., Bowker, K. E., Janowska, A., Holt, H. A. and Macgowan, A. P.: In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J. Antimicrob. Chemother., 44: 445-453 (1999).
3. Yamaguchi, T., Hirakata, Y., Izumikawa, K., Miyazaki, Y., Maesaki, S., Tomono, K., Yamada, Y., Kamihira, S. and Kohno, S.: In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob. Agents Chemother., 44: 1381-1382 (2000).
4. Zhanel, G. G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A. and Hoban, D. J.: Pharmacodynamic activity of telithromycin against macrolidesusceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J. Antimicrob. Chemother., 54: 1072-1077 (2004).
5. Edelstein, P. H. and Edelstein, M. A.: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob. Agents Chemother., 43: 90-95 (1999).
6. Miyashita, N., Fukano, H., Niki, Y. and Matsushima, T.: In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J. Antimicrob. Chemother., 48: 403-405 (2001).
7. Bryskier, A.: Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin. Microbiol. Infect., 6: 661-669 (2000).
8. Agouridas, C., Bonnefoy, A. and Chantot, J. F.: Antibacterial activity of RU 64004 (HMR 3004), a novel ketolide derivative active against respiratory pathogens. Antimicrob. Agents Chemother., 41: 2149-2158 (1997).
9. Bonnefoy, A., Girard, A. M., Agouridas, C. and Chantot, J. F.: Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother., 40: 85-90 (1997).
10. Yamazaki, H., Roeder, V., Vicat, P., Bonnat, C., Rainbeaud, M., Mauriac, C., Laplace, H., Jaulin, F., Haegele, K. D., Meili, M., Labbe, G., Abecassis, P-Y., Flor, M., Fougeat, S., Dupront, A., Coussediere, D. and Lenfant, B.: Pharmacokinetic studies of telithromycin in mouse, rat and dog. Jpn. J. Chemother., 51: 182-199 (2003).
11. Wilson, R., Dowling, R. B. and Jackson, A. D.: The biology of bacterial colonization and invasion of the respiratory mucosa. Eur. Respir. J., 9: 1523-1530 (1996).
12. Baldwin, D. R., Honeybourne, D. and Wise, R.: Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother., 36: 1171-1175 (1992).
13. Densen, P. and Mandell, G. L.: Phagocyte strategy vs. microbial tactics. Rev. Infect. Dis., 2: 817-838 (1980).
14. Yamaguchi, H., Haranaga, S., Widen, R., Friedman, H. and Yamamoto, Y.: Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages. Infect. Immun., 70: 2392-2398 (2002).
15. Horwitz, M. A. and Maxfield, F. R.: Legionella pneumophila inhibits acidification of its phagosome in human monocytes. J. Cell Biol., 99: 1936-1943 (1984).
16. Mckinney, J. D., Honer Zu Bentrup, K., Munoz-Elias, E. J., Miczak, A., Chen, B., Chan, W. T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., Jr. and Russell, D. G.: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 406: 735-738 (2000).
17. Ong, C. T., Dandekar, P. K., Sutherland, C., Nightingale, C. H. and Nicolau, D. P.: Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy, 51: 339-346 (2005).
18. Kadota, J., Ishimatsu, Y., Iwashita, T., Matsubara, Y., Tomono, K., Tateno, M., Ishihara, R., Muller-Serieys, C. and Kohno, S.: Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. Antimicrob. Agents Chemother., 46: 917-921 (2002).
19. Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E. and Wise, R.: Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother., 49: 31-40 (2002).
20. Butts, J. D.: Intracellular concentrations of antibacterial agents and related clinical implications. Clin. Pharmacokinet., 27: 63-84 (1994).
21. Antonini, J. M. and Reasor, M. J.: Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem. Pharmacol., 42: S151-156 (1991).
22. Rennard, S. I., Basset, G., Lecossier, D., O'donnell, K. M., Pinkston, P., Martin, P. G. and Crystal, R. G.: Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol., 60: 532-538 (1986).
23. Kohno, Y., Yoshida, H., Suwa, T. and Suga, T.: Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother., 26: 503-513 (1990).
24. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254 (1976).
25. Feng, N. H., Hacker, A. and Effros, R. M.: Solute exchange between the plasma and epithelial lining fluid of rat lungs. J. Appl. Physiol., 72: 1081-1089 (1992).
26. Widdicombe, J.: Airway and alveolar permeability and surface liquid thickness: theory. J. Appl. Physiol., 82: 3-12 (1997).
27. Wang, F., Daugherty, B., Keise, L. L., Wei, Z., Foley, J. P., Savani, R. C. and Koval, M.: Heterogeneity of claudin expression by alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol., 29: 62-70 (2003).
28. Forbes, B. and Ehrhardt, C.: Human respiratory epithelial cell culture for drug delivery applications. Eur. J. Pharm. Biopharm., 60: 193-205 (2005).
29. Sakagami, M.: In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev., 58: 1030-1060 (2006).
30. Florea, B. I., Van Der Sandt, I. C., Schrier, S. M., Kooiman, K., Deryckere, K., De Boer, A. G., Junginger, H. E. and Borchard, G.: Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br. J. Pharmacol., 134: 1555-1563 (2001).
31. Hamilton, K. O., Topp, E., Makagiansar, I., Siahaan, T., Yazdanian, M. and Audus, K. L.: Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J. Pharmacol. Exp. Ther., 298: 1199-1205 (2001).
32. Endter, S., Becker, U., Daum, N., Huwer, H., Lehr, C. M., Gumbleton, M. and Ehrhardt, C.: P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res., 328: 77-84 (2007).
33. Scheffer, G. L., Pijnenborg, A. C., Smit, E. F., Muller, M., Postma, D. S., Timens, W., Van Der Valk, P., De Vries, E. G. and Scheper, R. J.: Multidrug resistance related molecules in human and murine lung. J. Clin. Pathol., 55: 332-339 (2002).
34. Pachot, J. I., Botham, R. P., Haegele, K. D. and Hwang, K.: Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci., 6: 1-12 (2003).
35. Vazifeh, D., Preira, A., Bryskier, A. and Labro, M. T.: Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother., 42: 1944-1951 (1998).
36. Pascual, A., Ballesta, S., Garcia, I. and Perea, E. J.: Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells. Clin. Microbiol. Infect., 7: 65-69 (2001).
37. Seral, C., Michot, J. M., Chanteux, H., Mingeot-Leclercq, M. P., Tulkens, P. M. and Van Bambeke, F.: Influence of Pglycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother., 47: 1047-1051 (2003).
38. Laufen, H. and Wildfeuer, A.: Kinetics of the uptake of antimicrobial agents by human polymorphonuclear leucocytes. Arzneimittelforschung, 39: 233-235 (1989).
39. Vazifeh, D., Abdelghaffar, H. and Labro, M. T.: Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother., 41: 2099-2107 (1997).
40. Hand, W. L., King-Thompson, N. and Holman, J. W.: Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother., 31: 1553-1557 (1987).
41. Vazifeh, D., Abdelghaffar, H. and Labro, M. T.: Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin. Antimicrob. Agents Chemother., 46: 1364-1374 (2002).
42. Coffey, J. W. and de Duve C.: Digestive activity of lysosomes. I. The digestion of proteins by extracts of rat liver lysosomes., J. Biol. Chem., 12: 3255-3263 (1968).
43. Carlier, M. B., Zenebergh, A. and Tulkens, P. M.: Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J. Antimicrob. Chemother., 20 Suppl. B: 47-56 (1987).
44. De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P. and Van Hoof, F.: Lysosomotropic agents (Commentary.). Biochem. Pharmacol., 23: 2495-2531 (1974).
45. Shi, J., Montay, G. and Bhargava, V. O.: Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet., 44: 915-934 (2005).